Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Cumberland Pharmaceuticals Inc. - SIC # 2830 -
Ticker
Exchange
SIC #
Website
Latest Ticker
CPIX
Nasdaq
2830
www.cumberlandpharma.com
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Cumberland Pharmaceuticals Inc.
Cumberland Pharmaceuticals reports data from trial of ifetroban for DMD
- Feb 5th, 2025 10:23 am
Cumberland Pharmaceuticals' Duchenne Candidate Shows Improved Heart Function In Patients With Associated Heart Disease
- Feb 4th, 2025 6:31 pm
Cumberland Pharmaceuticals Announces Breakthrough Results from the Phase 2 FIGHT DMD Trial in Duchenne Muscular Dystrophy Heart Disease
- Feb 4th, 2025 12:30 pm
3 US Penny Stocks With Market Caps Over $30M
- Jan 16th, 2025 8:06 pm
3 Promising Penny Stocks With Market Caps Under $2B In US
- Dec 11th, 2024 12:09 am
Cumberland Stock Soars 90% After FDA Approval for Acetadote Dosing Change
- Dec 10th, 2024 6:39 pm
Why Is Cumberland Pharmaceuticals Stock Trading Over 100% on Tuesday?
- Dec 10th, 2024 5:08 pm
Sector Update: Health Care Stocks Steady Pre-Bell Tuesday
- Dec 10th, 2024 2:07 pm
FDA APPROVES ACETADOTEĀ® sNDA
- Dec 9th, 2024 9:05 pm
Cumberland Pharmaceuticals Third Quarter 2024 Earnings: US$0.11 loss per share (vs US$0.073 loss in 3Q 2023)
- Nov 10th, 2024 12:35 pm
Cumberland Pharmaceuticals Inc (CPIX) Q3 2024 Earnings Call Highlights: Navigating Challenges ...
- Nov 8th, 2024 11:00 pm
Cumberland: Q3 Earnings Snapshot
- Nov 7th, 2024 10:09 pm
Cumberland Pharmaceuticals Reports Third Quarter 2024 Financial Results and Company Update
- Nov 7th, 2024 9:05 pm
CUMBERLAND PHARMACEUTICALS RECEIVES FDA ORPHAN DRUG AND RARE PEDIATRIC DISEASE DESIGNATIONS FOR NEW TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY
- Nov 6th, 2024 10:21 pm
New Study Compares CaldolorĀ® (ibuprofen injection) to ketorolac
- Nov 5th, 2024 9:05 pm
CUMBERLAND PHARMACEUTICALS TO ANNOUNCE THIRD QUARTER 2024 FINANCIAL RESULTS
- Oct 31st, 2024 8:05 pm
Cumberland: Q2 Earnings Snapshot
- Aug 6th, 2024 9:00 pm
Cumberland Pharmaceuticals Reports 16% Sequential Revenue Growth in Second Quarter 2024
- Aug 6th, 2024 8:05 pm
CUMBERLAND PHARMACEUTICALS TO ANNOUNCE SECOND QUARTER 2024 FINANCIAL RESULTS
- Jul 30th, 2024 8:05 pm
Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX) Q1 2024 Earnings Call Transcript
- May 13th, 2024 12:50 pm
Scroll